Table 2 Multivariate analysis of CDA on progression-free survival (panel A) and overall survival (panel B) (cut-off 7.2 U/mg)

From: Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study

Parameter

DF

Parameter estimate

Standard error

Chi-square

Pr > Chisq

Hazard ratio

95% Confidence limits

Panel A

Age

1

−0.01623

0.01491

1.1847

0.2764

0.984

0.956–1.013

Sex: female

1

0.55047

0.28231

3.8020

0.0512

1.734

0.997–3.016

ECOG PS 1

1

0.50064

0.23169

4.6691

0.0307

1.650

1.048–2.598

ECOG PS 2

1

1.20025

0.46382

6.6964

0.0097

3.321

1.338–8.243

Stage IIIB

1

−0.49090

0.27448

3.1987

0.0737

0.612

0.357–1.048

CDA high > 7.2

1

0.47659

0.22985

4.2993

0.0381

1.611

1.026–2.527

Panel B

Age

1

−0.01091

0.01466

0.5536

0.4569

0.989

0.961–1.018

Sex: female

1

0.18483

0.25073

0.5434

0.4610

1.203

0.736–1.967

ECOG PS 1

1

0.64678

0.22697

8.1206

0.0044

1.909

1.224–2.979

ECOG PS 2

1

0.98242

0.41952

5.4839

0.0192

2.671

1.174–6.078

Stage IIIB

1

−0.81212

0.28671

8.0236

0.0046

0.444

0.253–0.779

CDA high > 7.2

1

0.58208

0.22099

6.9376

0.0084

1.790

1.161–2.760

  1. ECOG Eastern Cooperative Oncology Group, PS performance status, CDA cytidine deaminase
Back to article page